Magnetic Resonance Imaging in Detecting Cancer Progression in Patients With Early Stage Prostate Cancer Undergoing Active Surveillance

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed prostate cancer
• •Low-risk for progression, as evidenced by all of the following:
• •* Tumor stage ≤ T2a
• •* PSA ≤ 10 ng/mL
• •* Gleason score ≤ 7
• •Patients informed of treatment options and has already chosen to undergo active surveillance
• •* No decision to stop active surveillance
• •No node-positive or metastatic disease
• •PATIENT CHARACTERISTICS:
• •Willing to undergo MRI
• •Willing to undergo prostate biopsy
• •No contraindications to MRI that include, but not limited to, any of the following:
• •* Claustrophobia
• •* Anxiety
• •* Presence of metal or shrapnel in the body
• •* Pacemakers
• •* Old tattoos with metal-based dye material
• •No contraindication to prostate biopsy
• •No medical conditions, as deemed by the PI or associates, that would prevent or limit the patient participation on the protocol that include, but not limited to, any of the following:
• •* Severe coagulopathy
• •* History of severe bleeding
• •* Severe coronary artery disease
• •* Other comorbid conditions that limit life expectancy to less than 2 years
• •PRIOR CONCURRENT THERAPY:
• •No hormone therapy within the past year
• •No prior pelvic radiotherapy
• •No prior prostate resection including transurethral resection of prostate
• •Concurrent participation in other clinical studies (e.g., vitamin D, selenium) allowed provided active surveillance is continued